Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MEDS Stock Forecast 2025-2026
$0.61
Current Price
$548,434
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MEDS Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
MEDS Price Momentum
+1.7%
1 Week Change
-16.4%
1 Month Change
-90.9%
1 Year Change
-89.9%
Year-to-Date Change
-92.6%
From 52W High of $8.23
+31.5%
From 52W Low of $0.46
📊 TOP ANALYST CALLS
Did MEDS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Trxade is one of their latest high-conviction picks.
Latest MEDS Stock Price Targets & Analyst Predictions
MEDS has shown a year-to-date change of -89.9% and a 1-year change of -90.9%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MEDS. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MEDS Analyst Ratings
0
Buy
0
Hold
0
Sell
MEDS Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.61
Latest MEDS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MEDS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 1, 2023 | EF Hutton | Fozia Ahmed | Buy | Assumes | $1.25 |
| May 16, 2023 | EF Hutton | Constantine Davides | Buy | Maintains | $1.25 |
| Mar 28, 2023 | Maxim Group | Allen Klee | Buy | Maintains | $1.75 |
| Dec 9, 2021 | EF Hutton | Constantine Davides | Buy | Initiates | $4.50 |
| Dec 3, 2020 | National Securities Corporation | Buy | Initiates | $N/A | |
| Dec 3, 2020 | National Securities | Buy | Initiates | $N/A |
Scienture Holdings Inc. (MEDS) Competitors
The following stocks are similar to Trxade based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Scienture Holdings Inc. (MEDS) Financial Data
Scienture Holdings Inc. has a market capitalization of $548,434 with a P/E ratio of 0.0x. The company generates $8.27M in trailing twelve-month revenue with a 31.4% profit margin.
Revenue growth is +246.9% quarter-over-quarter, while maintaining an operating margin of -151.4% and return on equity of -3,290.0%.
Valuation Metrics
Market Cap
$548,434
Enterprise Value
$7.50M
P/E Ratio
0.0x
PEG Ratio
N/A
Price/Sales
0.1x
Growth & Margins
Revenue Growth (YoY)
+246.9%
Gross Margin
+6.0%
Operating Margin
-151.4%
Net Margin
+31.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+40.3%
Current Ratio
1.3x
Debt/Equity
0.0x
ROE
-3,290.0%
ROA
-142.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Scienture Holdings Inc. (MEDS) Business Model
About Scienture Holdings Inc.
What They Do
Invests in and manages diverse business portfolios.
Business Model
Scienture Holdings Inc. generates revenue by investing in and managing a diverse range of businesses that focus on innovative solutions and products. The company enhances operational efficiency in its subsidiaries, thereby creating value and fostering growth across various industries.
Additional Information
The company's strategic investments in technology-driven enterprises position it to improve productivity and adapt to market demands. By employing a diverse investment strategy, Scienture Holdings Inc. aims to mitigate risks while maximizing returns in the evolving financial landscape.
Company Information
Sector
Healthcare
Industry
Pharmaceutical Retailers
Employees
8
CEO
Mr. Surendra K. Ajjarapu
Country
United States
IPO Year
2019
Website
www.trxadehealth.comScienture Holdings Inc. (MEDS) Latest News & Analysis
Latest News
Quick Summary
Wellgistics Health, Inc. (NASDAQ:WGRX) announced new executive appointments to strengthen its leadership, aiming to enhance growth, operational scale, and shareholder value.
Why It Matters
Leadership changes often signal strategic shifts that can drive growth and operational efficiency, potentially boosting stock performance and shareholder value for Wellgistics Health.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
TRxADE Health, Inc. has changed its name to Scienture Holdings, Inc. and its ticker symbol to SCNX, while continuing to operate as a Nasdaq-listed company.
Why It Matters
The name and ticker change to Scienture Holdings, Inc. and SCNX may signal a new strategic direction, impacting investor perception and potential stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
TRxADE Health, Inc. will rebrand its subsidiary Scienture, LLC to Scienture Holdings, Inc. on September 23, 2024, trading under the new ticker NASDAQ:SCNX.
Why It Matters
The rebranding to Scienture Holdings and ticker change to SCNX may signal a strategic shift or focus, affecting investor perception and potentially impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team
1 year ago
Quick Summary
TRxADE Health, Inc. appointed Narasimhan Mani, Ph.D., MBA as President of its subsidiary Scienture. Shankar Hariharan remains as CEO, while Rahul Surana is promoted to Executive VP and COO.
Why It Matters
Leadership changes can impact company strategy and performance. New appointments often signal shifts in focus or direction, influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Scienture, Inc. has completed a $103 million all-stock business combination with TRxADE Health Inc., enhancing its position in the pharmaceutical sector.
Why It Matters
The $103 million all-stock merger signals potential growth for Scienture, Inc., impacting stock valuations and market positioning, which may influence investor sentiment and future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
TRxADE Health, Inc. declared a special cash dividend of $1.50 per share, payable on July 24, 2024, to shareholders of record as of July 19, funded by proceeds from asset sales.
Why It Matters
A special cash dividend of $1.50 per share signals strong cash flow and shareholder value, potentially attracting more investors and boosting stock price prior to the payout date.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MEDS Stock
What is Scienture Holdings Inc.'s (MEDS) stock forecast for 2026?
Analyst forecasts for Scienture Holdings Inc. (MEDS) are not currently available. The stock is trading at $0.61.
Is MEDS stock a good investment in 2026?
Analyst ratings for MEDS are not currently available. The stock is currently trading at $0.61. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MEDS stock?
Price predictions from Wall Street analysts for MEDS are not currently available. The stock is trading at $0.61.
What is Scienture Holdings Inc.'s business model?
Scienture Holdings Inc. generates revenue by investing in and managing a diverse range of businesses that focus on innovative solutions and products. The company enhances operational efficiency in its subsidiaries, thereby creating value and fostering growth across various industries.
What is the highest forecasted price for MEDS Scienture Holdings Inc.?
Price targets from Wall Street analysts for MEDS are not currently available. The stock is trading at $0.61.
What is the lowest forecasted price for MEDS Scienture Holdings Inc.?
Price targets from Wall Street analysts for MEDS are not currently available. The stock is trading at $0.61.
What is the overall MEDS consensus from analysts for Scienture Holdings Inc.?
Analyst ratings for MEDS are not currently available. The stock is trading at $0.61.
How accurate are MEDS stock price projections?
Stock price projections, including those for Scienture Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 6:01 PM UTC